Camp4 Therapeutics Corp
CAMP Nasdaq
SEC CIK 1736730
Follow Camp4 Therapeutics
Weekly email: filings, results
Revenue, last quarter
$1.9M
+138.9% vs same quarter last year
Net income
−$29M
−91.8% vs same quarter last year
EPS, diluted
−$0.37
+32.7% vs same quarter last year
Operating cash flow
−$8.2M
+27.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $3.5M | −$80.4M |
| FY24 | $652K | −$51.8M |
| FY23 | $350K | −$49.3M |
| FY22 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −1502.4% | −2298.5% |
| FY24 | −8142.3% | −7943.4% |
| FY23 | −14822.6% | −14083.1% |
| FY22 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$29.8M |
| FY24 | −$46M |
| FY23 | −$44.8M |
| FY22 | - |
- Camp4 Therapeutics
- Healthcare median
Show the numbers
| Year | Camp4 Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −2298.5% | −30.6% |
| FY24 | −7943.4% | −47% |
| FY23 | −14083.1% | −58% |
| FY22 | - | −80.4% |